Helix BioPharma Corp. (TSX, FSE: HBP; Pink Sheets: HXBPF) announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings. All ten of these patients, at all sampling time points, were found to have systemic interferon alpha-2b levels below the lower limit of detection (6.25 pg/mL) of the validated bioassay used in the study...
More...
More...